drugset / Trial / NCT06559488
IVB for Post-vitrectomy Hemorrhage in Diabetic Eyes
RandomizedParallel-groupSingle-blindTreatment
Summary
Recurrent vitreous hemorrhage following pars plana vitrectomy (PPV) for proliferative diabetic retinopathy remains a significant complication with reported incidence ranging from 11 to 75%. Early and late recurrences are associated with various factors, including residual blood, fibrovascular tissue, and neovascularization. Despite attempts to reduce this complication with therapies like anti-fibrinolytic agents, gas tamponade, and peripheral cryotherapy, the outcomes remain unsatisfactory.
Timeline
- Start
- 2018-04-02
- Primary completion
- 2019-03-31
- Completion
- 2019-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |